Indicated for: cancer
Route of administration: infusion
Substance: temsirolimus (antineoplastic agent)
ATC: L01EG01 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mammalian target of rapamycin (MTOR) kinase inhibitors)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid grapefruit and grapefruit juice.
Avoid live vaccines during treatment if contraindicated.
This medicine may affect the liver.
This medicine may increase the risk of infections.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Temsirolimus is an mTOR (mammalian target of rapamycin) inhibitor used for the treatment of advanced renal cancer and other types of tumors. It works by inhibiting the growth and proliferation of tumor cells, thereby reducing disease progression.
The medication is administered via intravenous infusion, usually once a week, as directed by a doctor. It is important for patients to be closely monitored during treatment to prevent potential complications.
Patients should be aware of potential side effects, such as skin rashes, fatigue, or elevated blood glucose levels. It is important to inform the doctor of any unusual symptoms.
Common side effects include skin rashes, fatigue, nausea, and increased cholesterol or glucose levels. In rare cases, severe reactions such as serious infections or kidney failure may occur. Patients should be informed of these risks before starting treatment.